血友病治療市場規模、佔有率、成長分析，按類型、按藥物類別、按治療方法、按患者、按治療、按給藥途徑、按最終用途、按地區 - 行業預測，2025 年至 2032 年

2023 年全球血友病治療市場規模價值 134 億美元，預計在預測期內（2025-2032 年）將從 2024 年的 142.8 億美元成長至 2032 年的 238.2 億美元。 %。

隨著醫療技術的進步、人們對疾病的認知不斷提高以及醫療保健機會的改善，全球血友病治療市場大幅擴張。市面上提供的產品種類繁多，包括重組凝血因子VIII和凝血因子IX製劑，這些產品對於治療A型血友病至關重要。這些濃縮物透過補充缺失的凝血因子顯著降低了出血風險。此外，基因療法是一種具有潛在變革性的治療方法，旨在糾正血友病核心的基因缺陷。關鍵成長要素包括血友病患病率上升、醫療支出增加、個人化醫療的轉變。隨著基因工程和生物技術的不斷進步，市場有望推出創新的治療方案，以改善血友病治療效果並探索最終的治療方法。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

血友病治療市場規模（按類型）

• 市場概況
• A型血友病A
• B型血友病

血友病治療市場規模（依藥物類別分類）

• 市場概況
• 加壓素
• 凝血因子

血友病治療市場規模（依治療方法）

• 市場概況
• 重組凝血因子濃縮物治療
• 血漿源性凝血因子濃縮物治療
• 非因子替代療法
• 半衰期延長產品
• 去氨加壓素
• 抗纖溶藥物
• 基因治療產品
• 其他

血友病治療市場規模（依患者分類）

• 市場概況
• 小兒科
• 對於成年人

血友病治療市場規模（依治療方法）

• 市場概況
• 預防
• 一經請求

按給藥途徑分類的血友病治療市場規模

• 市場概況
• 注射
• 鼻腔噴劑
• 口服

血友病治療市場規模（依最終用途）

• 市場概況
• 醫院
• 診所
• 血友病治療中心
• 其他

血友病治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Pfizer Inc.（United States）
• Bayer AG（Germany）
• Novo Nordisk A/S（Denmark）
• CSL Behring（Australia）
• BioMarin Pharmaceutical Inc.（United States）
• Sangamo Therapeutics（United States）
• Octapharma AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Takeda Pharmaceutical Company Limited（Japan）
• Grifols SA（Spain）
• Alnylam Pharmaceuticals, Inc.（United States）
• Biogen Inc.（United States）
• Kedrion Biopharma（Italy）
• SOBI（Sweden）
• Genentech, Inc.（United States）
• Shire plc（United Kingdom）
• Aptevo Therapeutics（United States）
• Catalyst Biosciences（United States）
• uniQure NV（Netherlands）

結論和建議

Global Hemophilia Treatment Market size was valued at USD 13.4 billion in 2023 and is poised to grow from USD 14.28 billion in 2024 to USD 23.82 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

The global Hemophilia Treatment Market has experienced remarkable expansion, driven by medical technology advancements, heightened awareness of the disorder, and improved healthcare access. The market offers a diverse range of products, including clotting factor concentrates like recombinant factor VIII and factor IX, essential for treating hemophilia A and B, respectively. These concentrates significantly decrease bleeding risks by replenishing absent clotting factors. Additionally, gene therapy represents a groundbreaking potential cure, aiming to rectify the genetic defects at the disorder's core. Key growth factors include the rising prevalence of hemophilia, increasing healthcare spending, and a shift towards personalized medicine. With the continuous evolution in genetic engineering and biotechnology, the market is poised for innovative treatment solutions to enhance outcomes and seek definitive cures for hemophilia.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemophilia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemophilia Treatment Market Segmental Analysis

Global Hemophilia Treatment Market is segmented by Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use and region. Based on Type, the market is segmented into Hemophilia A and Hemophilia B. Based on Drug Class, the market is segmented into Vasopressin and Coagulation factors. Based on Therapy, the market is segmented into Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Extended half-life products, Desmopressin, Antifibrinolytic agents, Gene therapy products and Others. Based on Patient, the market is segmented into Pediatric and Adult. Based on Treatment, the market is segmented into Prophylaxis and On demand. Based on Route of Administration, the market is segmented into Injectable, Nasal spray and Oral. Based on End-use, the market is segmented into Hospitals, Clinics, Hemophilia treatment centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemophilia Treatment Market

The global Hemophilia Treatment market is primarily driven by continuous technological advancements in the realm of diagnostics and therapies. Leading players in the industry are focused on developing innovative, cutting-edge tools and medications designed to enhance the effectiveness and precision of hemophilia treatment. Furthermore, substantial investments aimed at expanding specialized hemophilia treatment centers (HTCs) worldwide contribute significantly to the positive market outlook. The combination of enhanced technology and the growth of dedicated treatment facilities is expected to propel the market forward, ensuring better patient outcomes and increased accessibility to quality care for individuals living with hemophilia.

Restraints in the Global Hemophilia Treatment Market

The Global Hemophilia Treatment market faces significant restraints due to the stringent regulatory approval processes enforced by health authorities. These rigorous requirements necessitate that manufacturers undergo comprehensive assessments of safety and efficacy, which can be both time-consuming and resource-heavy. As a result, the lengthy approval times can hinder the market entry of innovative treatment options, ultimately stalling growth and limiting patient access to new therapies. This regulatory burden can create barriers for companies seeking to introduce advancements in hemophilia care, thereby impacting the overall development and competitiveness of the market.

Market Trends of the Global Hemophilia Treatment Market

The global hemophilia treatment market is witnessing significant growth driven by an increase in the incidence of genetic disorders and a rising population of hemophiliac patients. Enhanced diagnostic capabilities and growing awareness around preventive treatment options are further propelling market expansion. Major pharmaceutical firms are realizing lucrative opportunities due to heightened diagnosis rates, while regulatory bodies are initiating campaigns to promote early diagnosis and testing for newborns. This awareness boost not only accelerates treatment accessibility but also invigorates research and development efforts, as companies seek innovative solutions amidst a limited therapeutic landscape. Overall, these trends signal a robust growth trajectory for the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Hemophilia Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B

Global Hemophilia Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Vasopressin
• Coagulation factors

Global Hemophilia Treatment Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Recombinant coagulation factor concentrates therapy
• Plasma derived coagulation factor concentrates therapy
• Non-factor replacement therapy
• Extended half-life products
• Desmopressin
• Antifibrinolytic agents
• Gene therapy products
• Others

Global Hemophilia Treatment Market Size by Patient & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult

Global Hemophilia Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Prophylaxis
• On demand

Global Hemophilia Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Injectable
• Nasal spray
• Oral

Global Hemophilia Treatment Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Hemophilia treatment centers
• Others

Global Hemophilia Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • US
  • Canada
• Europe (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOBI (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptevo Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• uniQure N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations